Ruti Aga’s Six-Year Ban: The Forged Medical Record, Not the Drug Alone, Became Decisive

Ruti Aga won a half-marathon in China in March. The available report does not give her time, splits, opponents or the race’s full date. Yet that race has become the decisive entry in her career record: according to the Athletics Integrity Unit (AIU), a sample contained methylprednisolone, and a medical document later offered to support treatment for a knee injury was found to be forged. The case has resulted in a six-year ban.

The first essential correction concerns the drug’s classification. Calling methylprednisolone a “banned steroid” is technically misleading. It is a glucocorticoid, not an anabolic steroid. Glucocorticoids fall under class S9 of the WADA Prohibited List, with an in-competition prohibition applying to specified routes—injectable, oral or rectal. The question is therefore not only whether the drug was used, but how and when it was administered, and on what medical basis.

The central development is not merely the positive sample; it is the forged medical paperwork that turned a possible treatment explanation into an additional disciplinary violation.

According to the AIU account, Aga cited treatment for a knee injury. Use of the drug for inflammation or pain around a knee can have a medical context; medical plausibility, however, does not automatically make its use compliant. The in-competition restriction and route of administration matter. If the treatment was genuine, original records, the clinician’s identity, the date, the dose and the method of administration would be central to a defence.

The document trail described in the report points elsewhere. The purported prescription was linked to a clinic that did not exist. The family member who issued it was not a registered doctor. That person said an old prescription pad from a former workplace had been used, while the clinic disowned the document. These are three separate verification points—the institution, the prescriber’s credentials and the document’s origin—and all came under scrutiny.

In integrity reporting, my first task is to make the language precise: what was found in the sample, when the rules apply to that substance, and what conduct the panel found established. Years of watching competition have taught me that early headlines often flatten “doping” into a single kind of story. But substance class, administration route and competition timing can change the legal picture. Here, the word “steroid” gives readers the wrong impression.

The sanction arithmetic matters too. The available account gives two years for the presence violation and four years for tampering or misleading conduct during the investigation. Together, they make six years. The ban is stated to run from September 10, and the provisional suspension is also reported to have begun on that date. The source does not state the year, so it would be unwise to convert the ban into a specific calendar end date without confirmation.

That duration tells us more than the number alone. The distinction between the two-year and four-year portions indicates that documents and statements made during the investigation were central to the case. The AIU account says the family member’s role and the explanation about the old prescription pad were examined. The matter therefore went beyond the laboratory result. The available material does not establish the full legal reasoning by which every possible defence was rejected; that requires the reasoned decision.

Aga is 32. A six-year ban could keep her out of competition until about age 38. That calculation is not a formal verdict on her career, but it represents a serious practical obstacle given the demands of elite marathon selection and a return to competition. She will be ineligible for international competition during the ban. Her 2026 Tokyo Marathon victory and three runner-up finishes at World Marathon Majors remain notable parts of her career. The available account does not say which earlier results, if any, have been annulled. Nor should the result or prize money from the Chinese race be described as definitively forfeited without the relevant decision.

That distinction between record and inference matters. The report says Aga won a half-marathon in China; it gives no time. We cannot calculate her level against a world record, assess the field or judge her form that day. It also takes care to avoid treating a win as proof of a particular race label or testing arrangement. The AIU investigation and sample are important facts, but the available material does not include the event’s full name, exact date or results sheet.

The credibility of the documentation became more decisive than the potential medical use of the drug. If treatment genuinely took place, independently verifiable medical records should have supported it. The attempt to use a forged prescription closed that route and brought an additional violation into the case. This does not declare the drug harmless. It explains that the rules assess the same drug according to timing and route, while misleading investigators creates a separate responsibility.

In distance running, injury management is not simply a private matter for the athlete. Marathoners prepare for months while navigating travel, appearance fees and limited racing opportunities. An urgent response to knee pain may be medically real. But treatment without a qualified clinician, proper records and knowledge of the Prohibited List can expose an athlete to serious rule risks. This case does not prove a regional practice; it would be irresponsible to generalize about all East African road running from one case. It does, however, raise a fair question about how consistently elite athletes receive qualified sports-medicine support and anti-doping guidance.

Institutions also have a responsibility. Athletes need clear advice that the in-competition restriction for glucocorticoids depends on the route and timing of administration. Before treatment, clinicians should understand the Prohibited List and the therapeutic use exemption (TUE) process. The available facts do not establish that a TUE was required in every possible version of this case. Nor should a universal washout period be stated: appropriate guidance depends on the specific drug, dose, route and applicable rules. The short AIU account also does not fully establish whether genuine treatment records existed.

Counting the provisional suspension from September 10 is procedurally important because time served under that suspension may count toward the total period. But the date can only be fully understood once the year and applicable rules are confirmed. Likewise, any appeal analysis requires the decision date, the appeal forum and the relevant deadline. The documentary findings are serious, but a news report should not present possible legal options as settled outcomes.

The case also matters because early reports often become public memory. A short but inaccurate phrase such as “banned steroid” can give readers a false understanding of both the substance and the rule. A correction may follow, but the first framing can endure. The distinction between glucocorticoids and anabolic steroids should remain clear; so should the distinction between a positive sample, a documentary violation and the length of the sanction.

Aga’s case does not overturn the competitive landscape. Her major results listed in the available account include the 2026 Tokyo Marathon title and three Major runner-up finishes; the account does not cite a global championship medal. To claim that her suspension changes Ethiopia’s selection prospects would require national selection data or an official response. For now, the more concrete question lies outside the competition: who decided on the treatment, who prepared the document, and did the athlete have access to qualified medical support?

I trust patterns more than podiums, because patterns tell you who paid for the podium. But a pattern requires comparable documents across multiple cases; blaming an entire training or management system on one incident would not be reporting. The available facts support a narrower conclusion: the treatment may have had a plausible medical context, but the prescription presented did not withstand verification, and conduct during the investigation extended the sanction.

The six-year ban effectively removes Aga from the next competitive cycle. Further clarity must come from the full decision—particularly the specific rule violations, the end date, any annulled results and the status of an appeal. The practical question for sport administrators is this: can every elite runner access medical and anti-doping guidance early enough to prevent a real injury from becoming a forged-paperwork case?